Tablet Rifagut (Rifaximin)

What Is It?

Rifagut is a brand name for Rifaximin, a derivative of rifampin. It is available in three strengths: 200 mg, 400 mg, and 550 mg. The key feature of rifaximin is that it is minimally absorbed - systemic absorption is less than 0.5% after oral intake - meaning its action stays almost entirely in the gut lumen.

Mechanism of Action

Rifaximin inhibits bacterial RNA synthesis by binding to the beta subunit of DNA-dependent RNA polymerase, preventing transcription. It is active against both gram-positive and gram-negative aerobes and anaerobes.

Fecal concentrations are very high: after a 3-day course for travelers' diarrhea, fecal concentrations reach ~8,000 mcg/g
Because of minimal systemic absorption, it does not cause the cytochrome P450-mediated drug interactions seen with other rifamycins (like rifampin)

(Katzung's Basic and Clinical Pharmacology, 16th Ed.)

Indications and Doses

Indication	Dose	Duration
Traveler's Diarrhea (due to non-invasive E. coli)	200 mg three times daily	3 days
IBS with Diarrhea (IBS-D)	550 mg three times daily	14 days
Hepatic Encephalopathy (prevention of recurrence)	550 mg twice daily	Long-term / ongoing
Small Intestinal Bacterial Overgrowth (SIBO)	400 mg three times daily	7-10 days
Diverticulitis (cyclic, off-label)	400 mg twice daily	1 week/month
Recurrent/Refractory C. difficile	Used as an adjunct	Variable

Important: Rifaximin for travelers' diarrhea should NOT be used when diarrhea is complicated by fever, blood in stool, or caused by invasive pathogens other than E. coli.

IBS-D Evidence

Two large phase III RCTs (>1,200 patients each) showed rifaximin 550 mg TDS x 14 days gave significantly better adequate relief of IBS symptoms vs. placebo. A meta-analysis (5 studies) found:

Global IBS improvement: OR 1.57 (95% CI 1.22-2.01; NNT = 10.2)
Bloating improvement: OR 1.59 (95% CI 1.23-1.96; NNT = 10)

Patients can receive up to 2 additional retreatment courses for symptom recurrence, and retreatment has been shown to remain effective. (Yamada's Textbook of Gastroenterology, 7th Ed.)

Hepatic Encephalopathy

Rifaximin 550 mg twice daily is used to prevent recurrent episodes of hepatic encephalopathy (HE) in patients with liver disease. It works by reducing gut-derived ammonia production by modulating intestinal microbial function - interestingly, it affects microbial metabolic activity rather than composition, leading to increases in serum saturated and unsaturated fatty acids. (Goldman-Cecil Medicine)

Side Effects

Generally very well tolerated. Most common adverse effects include:

Nausea
Abdominal pain / cramping
Headache
Upper respiratory tract infection / nasopharyngitis
Diarrhea (paradoxically, as a mild effect)

Risk of C. difficile colitis is very low; in initial IBS treatment trials, there were zero cases of CDI. (Yamada's Textbook of Gastroenterology)

Contraindications / Cautions

Not for diarrhea with fever or bloody stools (may indicate invasive pathogen - rifaximin not effective)
Hypersensitivity to rifaximin or other rifamycins
Use with caution in severe hepatic impairment (small increased systemic absorption)
Drug interactions: P-glycoprotein inhibitors (e.g., lasmiditan, tepotinib, berotralstat, lonafarnib) can increase rifaximin levels

Key Advantages Over Systemic Antibiotics

Stays in the gut - minimal systemic side effects
No CYP450 drug interactions
Low risk of systemic adverse effects
Does not significantly disturb the overall gut microbiome composition - only modest, transient changes

Summary: Rifagut (Rifaximin) is a gut-selective antibiotic used for traveler's diarrhea, IBS-D, hepatic encephalopathy prevention, and SIBO. Its hallmark is near-zero systemic absorption, making it safe and well-tolerated with a local gut action profile.

This is a shared conversation. Sign in to Orris to start your own chat.